Results 141 to 150 of about 17,431 (301)

Abstracts

Molecular Oncology, Volume 19, Issue S1, Page 1-895, June 2025.
Abstracts submitted to the ‘EACR 2025 Congress: Innovative Cancer Science’, from 16–19 June 2025 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source

Post‐Translational Modifications of RNA‐Modifying Proteins in Cellular Dynamics and Disease Progression

Advanced Science, Volume 11, Issue 44, November 26, 2024.
Post‐translational modifications (PTMs) of RNA‐modifying proteins, such as METTL3 and METTL14, modulate their activity and interactions, impacting transcription, signaling pathways, and immune responses. These processes are crucial in driving cancer progression, immune evasion, and pathogen responses, making PTMs of RNA modifiers potential therapeutic ...
Yunfan Lin, Pei Lin, Ye Lu, Jiarong Zheng, Yucheng Zheng, Xiangyu Huang, Xinyuan Zhao, Li Cui   +7 more
wiley   +1 more source

Olaparib Enhances the Efficacy of Third‐Generation Oncolytic Adenoviruses Against Glioblastoma by Modulating DNA Damage Response and p66shc‐Induced Apoptosis

CNS Neuroscience &Therapeutics, Volume 30, Issue 11, November 2024.
On the basis of oncolytic adenovirus TS‐2021 infection caused PARP activation. The combination of TS‐2021 and olaparib increases virus titer, p66shc phosphorylation, reactive oxygen species production, and DNA damage, leading to synergistic apoptosis in GBM.
Yida Liu, Sheng Fang, Peiwen Wang, Junwen Zhang, Fusheng Liu   +4 more
wiley   +1 more source

Genetically Engineered Cell Membrane Nanovesicles for Oncolytic Adenovirus Delivery: A Versatile Platform for Cancer Virotherapy.

Nano letters (Print), 2019
Currently, various oncolytic adenoviruses (OA) are being explored in both preclinical and clinical virotherapy. However, the pre-existing neutralizing antibodies (nAbs) and poor targeting delivery are major obstacles for systemically administered OA ...
Peng Lv, Xuan Liu, Xiaomei Chen, Chao Liu, Yang Zhang, Chengchao Chu, Junqing Wang, Xiaoyong Wang, Xiaoyuan Chen, G. Liu   +9 more
semanticscholar   +1 more source

Tumor treatment with chemo-virotherapy and MEK inhibitor: A mathematical model of Caputo fractional differential operator

Alexandria Engineering Journal, 2023
Mitogen-activated protein kinase (MEK) inhibitors and oncolytic virotherapy are identified as promising cancer therapies that can enhance the efficacy of other cancer treatments.
M. Moksud Alam, S.M.E.K. Chowdhury, J.T. Chowdhury, Mohammad Mahmud Hasan, M.A. Ullah, Shams Forruque Ahmed   +5 more
doaj  

Oncolytic Herpes Simplex Virus Inhibits Pediatric Brain Tumor Migration and Invasion [PDF]

, 2017
Paediatric high grade glioma (pHGG) and diffuse intrinsic pontine glioma (DIPG) are invasive tumours with poor survival. Oncolytic virotherapy, initially devised as a direct cytotoxic treatment, is now also known to act via immune-mediated mechanisms ...
Bartolini, Caretti, Cockle, Cockle, Demuth, Dumontet, Etienne-Manneville, Etienne-Manneville, Etienne-Manneville, Fangusaro, Ganguly, Grimes, Hargrave, Harrow, Jones, Kaufman, Khatua, Kirschner, Liao, Louis, Louis, Luo, Lyman, Naghavi, Papanastassiou, Peris, Prestwich, Radtke, Rampling, Reed, Russell, Schroeder, Schulze, Sun, Taylor, Tran, Turnbull, Waterman-Storer, Wollmann   +38 more
core   +3 more sources

Beyond the Gut: The intratumoral microbiome's influence on tumorigenesis and treatment response

Cancer Communications, Volume 44, Issue 10, Page 1130-1167, October 2024.
Abstract The intratumoral microbiome (TM) refers to the microorganisms in the tumor tissues, including bacteria, fungi, viruses, and so on, and is distinct from the gut microbiome and circulating microbiota. TM is strongly associated with tumorigenesis, progression, metastasis, and response to therapy.
Hao Zhang, Li Fu, Xinwen Leiliang, Chunrun Qu, Wantao Wu, Rong Wen, Ning Huang, Qiuguang He, Quan Cheng, Guodong Liu, Yuan Cheng   +10 more
wiley   +1 more source

Breast cancer immunotherapy: Realities and advances

Cancer Innovation, Volume 3, Issue 5, October 2024.
In this article, we aim to summarize the most recent data available in breast cancer immunotherapy, including the results of ongoing clinical trials and approved therapies used as monotherapies or in combination with conventional treatments. Abstract Breast cancer (BC) is the most common malignant tumor and the main cause of death in women worldwide ...
Aixa Medina, Jeismar Carballo, Eglys González‐Marcano, Isaac Blanca, Ana F. Convit   +4 more
wiley   +1 more source

Combined therapy with oncolytic adenoviruses encoding TRAIL and IL-12 genes markedly suppressed human hepatocellular carcinoma both in vitro and in an orthotopic transplanted mouse model [PDF]

, 2016
Background: Gene-based virotherapy mediated by oncolytic viruses is currently experiencing a renaissance in cancer therapy. However, relatively little attention has been given to the potentiality of dual gene virotherapy strategy as a novel therapeutic ...
���������
core   +1 more source

Talimogene laherparepvec: First in class oncolytic virotherapy

Human Vaccines & Immunotherapeutics, 2018
Oncolytic viruses represent a novel drug class in which native or modified viruses mediate tumor regression through selective replication within and lysis of tumor cells as well as induction of systemic antitumor immunity capable of eradicating tumor at ...
R. Conry, Brian C. Westbrook, Svetlana B. McKee, T. G. Norwood   +3 more
semanticscholar   +1 more source